Pontine Glioma - Pipeline Review, H2 2016

Published: Nov, 2016 | Pages: 77 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pontine Glioma - Pipeline Review, H2 2016, provides an overview of the Pontine Glioma (Oncology) pipeline landscape.

Pontine gliomas are highly aggressive and difficult to treat brain tumors found at the base of the brain. One of the most common types is diffuse intrinsic pontine glioma (DIPG). DIPG affects the pons portion of the brainstem, rendering nervous system function impossible. Symptoms include double vision, inability to close the eyelids completely, dropping one side of the face, and difficulty chewing and swallowing.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pontine Glioma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Pontine Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pontine Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pontine Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 3, 4 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 2 molecules, respectively.Pontine Glioma.

Pontine Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pontine Glioma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Pontine Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pontine Glioma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pontine Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pontine Glioma (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pontine Glioma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pontine Glioma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Pontine Glioma Overview 7
Therapeutics Development 8
Pipeline Products for Pontine Glioma - Overview 8
Pipeline Products for Pontine Glioma - Comparative Analysis 9
Pontine Glioma - Therapeutics under Development by Companies 10
Pontine Glioma - Therapeutics under Investigation by Universities/Institutes 11
Pontine Glioma - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Pontine Glioma - Products under Development by Companies 14
Pontine Glioma - Products under Investigation by Universities/Institutes 15
Pontine Glioma - Companies Involved in Therapeutics Development 16
AbbVie Inc 16
Arog Pharmaceuticals Inc 17
Burzynski Research Institute Inc 18
Loxo Oncology, Inc. 19
Medicenna Therapeutics Inc 20
Medivation Inc 21
Midatech Pharma Plc 22
Novogen Ltd 23
Sanofi 24
ZIOPHARM Oncology Inc 25
Pontine Glioma - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
(A-10 + AS-21) - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
AdRTSIL-12 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
cabazitaxel - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Cellular Immunotherapy for Pediatric Diffuse Intrinsic Pontine Glioma - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
crenolanib besylate - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
depatuxizumab mafodotin - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
LOXO-101 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
MDNA-55 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
MTX-110 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
MTX-111 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
ORX-101 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
p28 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
pidilizumab - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
Trilexium - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
Vaccine for Pontine Glioma - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
Vimo-101 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Pontine Glioma - Dormant Projects 72
Pontine Glioma - Product Development Milestones 73
Featured News & Press Releases 73
Jul 11, 2016: AbbVie Receives U.S. FDA Rare Pediatric Disease Designation for Investigational ABT-414 for the Treatment of a Type of Pediatric Brain Tumor known as Diffuse Intrinsic Pontine Glioma (DIPG) 73
Feb 19, 2016: Novogen Patent Covering Trilexium Has Been Proceeded To Grant 73
Jun 04, 2015: Studies Confirm TRXE-009 Crosses the Blood-brain Barrier 74
May 08, 2015: Australian Studies Confirm TRXE-009 Kills Resistant Paediatric Brain Cancer Cells 75
Appendix 76
Methodology 76
Coverage 76
Secondary Research 76
Primary Research 76
Expert Panel Validation 76
Contact Us 76
Disclaimer 77

List of Tables

Number of Products under Development for Pontine Glioma, H2 2016 8
Number of Products under Development for Pontine Glioma - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Pontine Glioma - Pipeline by AbbVie Inc, H2 2016 16
Pontine Glioma - Pipeline by Arog Pharmaceuticals Inc, H2 2016 17
Pontine Glioma - Pipeline by Burzynski Research Institute Inc, H2 2016 18
Pontine Glioma - Pipeline by Loxo Oncology, Inc., H2 2016 19
Pontine Glioma - Pipeline by Medicenna Therapeutics Inc, H2 2016 20
Pontine Glioma - Pipeline by Medivation Inc, H2 2016 21
Pontine Glioma - Pipeline by Midatech Pharma Plc, H2 2016 22
Pontine Glioma - Pipeline by Novogen Ltd, H2 2016 23
Pontine Glioma - Pipeline by Sanofi, H2 2016 24
Pontine Glioma - Pipeline by ZIOPHARM Oncology Inc, H2 2016 25
Assessment by Monotherapy Products, H2 2016 26
Assessment by Combination Products, H2 2016 27
Number of Products by Stage and Target, H2 2016 29
Number of Products by Stage and Mechanism of Action, H2 2016 31
Number of Products by Stage and Route of Administration, H2 2016 33
Number of Products by Stage and Molecule Type, H2 2016 35
Pontine Glioma - Dormant Projects, H2 2016 72